HomeAbout

TL;DR CNBC


Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start - TL;DR CNBC

Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start

Publishing timestamp: 2024-02-20 14:15:29


Summary

The launch of the Alzheimer's drug Leqembi by Biogen and Eisai is off to a slow start, but demand is rising. Apple's new mixed reality headset, Vision Pro, has received mixed reviews with some users experiencing discomfort like headaches and motion sickness. Experts suggest taking breaks and moderating usage to alleviate symptoms.


Sentiment: MIXED

Tickers: BIIB4523.T-JPESALY

Keywords: health care industrybiogen inceisai co ltdsciencebiotech and pharmaceuticalsbusiness news

Source: https://www.cnbc.com/2024/02/20/healthy-returns-alzheimers-drug-leqembi-launch-apple-vision-pro-nausea.html


Developed by Leo Phan